Recent Company News

• 08:44 AM ET Aug 18, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:53 AM ET Aug 27, 2025
  

  Bayer's NDA for gadoquatrane accepted for review by the FDA (€28.73, +0.14)

• 09:01 AM ET Aug 21, 2025
  

  Health Canada grants marketing authorization for an additional indication of Bayer's NUBEQA (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) (€27.92, -0.03)

• 04:33 PM ET Aug 18, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:04 AM ET Aug 18, 2025
  

  Bayer's Monsanto reaches agreements in principle to resolve additional PCB cases at Sky Valley Education Center (€27.07, +0.02)

• 01:04 PM ET Aug 15, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 17-Aug

• 03:11 AM ET Aug 12, 2025
  

  Bayer AG and Kumquat Biosciences enter collaboration in precision oncology; Kumquat will receive up to a total payment of $1.3B (€25.71, 0.00)